 Shares of Alnylam Pharmaceuticals Inc. ALNY, 1.44 soared 57.0 in premarket trading on Wednesday after the company said its investigational RNAi therapeutic for a type of heart failure met the primary endpoint in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled study enrolled 360 adult patients in 21 countries. 